Patents by Inventor James E. Crowe, Jr.

James E. Crowe, Jr. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230122364
    Abstract: The present disclosure is directed to antibodies binding to and neutralizing tire coronavirus designated SARS-CoV-2 and methods for use thereof.
    Type: Application
    Filed: March 26, 2021
    Publication date: April 20, 2023
    Inventors: James E. CROWE, Jr., Seth ZOST, Robert CARNAHAN, Pavlo GILCHUK
  • Publication number: 20230085393
    Abstract: The present disclosure is directed to antibodies binding to and neutralizing Zika vims and methods for use thereof.
    Type: Application
    Filed: November 9, 2020
    Publication date: March 16, 2023
    Applicant: Vanderbilt University
    Inventors: James E. Crowe, Jr., Robert H. Carnanhan, Pavlo Gilchuk
  • Publication number: 20230078330
    Abstract: The present disclosure is directed to antibodies binding to and neutralizing dengue virus and methods for use thereof.
    Type: Application
    Filed: January 19, 2021
    Publication date: March 16, 2023
    Inventors: James E. CROWE, JR., Ralph BARIC, Eva HARRIS
  • Publication number: 20230072640
    Abstract: The present disclosure is directed to antibodies binding to and neutralizing Yellow Fever Virus and methods for use thereof.
    Type: Application
    Filed: July 29, 2022
    Publication date: March 9, 2023
    Inventor: James E. CROWE, Jr.
  • Publication number: 20230073075
    Abstract: The present disclosure is directed to antibodies binding to and neutralizing henipavirus and methods for use thereof. Thus, in accordance with the present disclosure, there is provided a method of detecting a henipavirus infection in a subject comprising (a) contacting a sample from said subject with an antibody or antibody fragment having clone-paired heavy and light chain CDR sequences from Tables 3 and 4, respectively; and (b) detecting henipavirus in said sample by binding of said antibody or antibody fragment to a henipavirus antigen in said sample.
    Type: Application
    Filed: November 12, 2020
    Publication date: March 9, 2023
    Applicant: Vanderbilt University
    Inventor: James E. CROWE, Jr.
  • Patent number: 11596679
    Abstract: The present disclosure relates to compositions and methods for inducing an adaptive immune response against Hepatitis C virus (HCV) in a subject. In some embodiments, the present disclosure provides a composition comprising a nucleic acid molecule encoding a HCV antigen, an HCV antigen, an adjuvant, or a combination thereof. For example, in some embodiments, the composition comprises a vaccine comprising a nucleic acid molecule encoding a HCV antigen, an HCV antigen, an adjuvant, or a combination thereof.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: March 7, 2023
    Assignees: VANDERBILT UNIVERSITY, THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, THE JOHNS HOPKINS UNIVERSITY
    Inventors: James E. Crowe, Jr., Andrew Flyak, Justin Bailey, Stuart Ray, George Shaw
  • Publication number: 20230063625
    Abstract: The present disclosure is directed to antibodies binding to and neutralizing Rift Valley Fever Virus and methods for use thereof.
    Type: Application
    Filed: January 8, 2021
    Publication date: March 2, 2023
    Applicant: Vanderbilt University
    Inventor: James E. CROWE, JR.
  • Publication number: 20230065377
    Abstract: The present disclosure is directed to antibodies binding to and neutralizing alphavirus, such as EEEV, WEEV or VEEV, and methods for use thereof. Thus, in accordance with the present disclosure, a method of detecting an alphavirus infection in a subject comprising (a) contacting a sample from said subject with an antibody or antibody fragment having clone-paired heavy and light chain CDR sequences from Tables 3 and 4, respectively; and (b) detecting alphavirus in said sample by binding of said antibody or antibody fragment to an alphavirus antigen in said sample.
    Type: Application
    Filed: August 31, 2020
    Publication date: March 2, 2023
    Inventor: JAMES E. CROWE, JR.
  • Publication number: 20230054956
    Abstract: The present disclosure is directed to antibodies binding to and neutralizing norovirus and methods for use thereof.
    Type: Application
    Filed: June 20, 2022
    Publication date: February 23, 2023
    Inventor: James E. CROWE, Jr.
  • Patent number: 11524994
    Abstract: The present disclosure is directed to antibodies binding to human respiratory syncytial virus F protein, including both neutralizing and non-neutralizing antibodies, and methods for use thereof.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: December 13, 2022
    Assignee: VANDERBILT UNIVERSITY
    Inventors: James E. Crowe, Jr., Jarrod Mousa
  • Publication number: 20220387578
    Abstract: The present disclosure is directed to peptide antigens derived from a previously undefined epitope on influenza A virus hemagglutinin and methods for use thereof.
    Type: Application
    Filed: May 16, 2020
    Publication date: December 8, 2022
    Inventors: James E. CROWE, Jr., Xiaozhen HU, William SCHIEF
  • Publication number: 20220380442
    Abstract: The present disclosure is directed to antibodies binding to and neutralizing hantavirus and methods for use thereof.
    Type: Application
    Filed: November 10, 2020
    Publication date: December 1, 2022
    Applicant: Vanderbilt University
    Inventor: James E. CROWE, Jr.
  • Publication number: 20220289828
    Abstract: The present disclosure is directed to antibodies binding to enterovirus D68 (EV-D68) and methods for use thereof.
    Type: Application
    Filed: July 24, 2020
    Publication date: September 15, 2022
    Inventors: JAMES E. CROWE, Jr., MATTHEW R. VOGT
  • Publication number: 20220281958
    Abstract: The present disclosure is directed to antibodies binding to and neutralizing the coronavirus designated SARS-CoV-2 and methods for use thereof.
    Type: Application
    Filed: March 18, 2022
    Publication date: September 8, 2022
    Applicant: Vanderbilt University
    Inventors: James E. CROWE, JR., Seth ZOST, Robert CARNAHAN, Pavlo GILCHUK
  • Patent number: 11345743
    Abstract: The present disclosure is directed to antibodies binding to and neutralizing Chikungunya virus (CHIKV) and methods for use thereof.
    Type: Grant
    Filed: October 10, 2019
    Date of Patent: May 31, 2022
    Assignee: VANDERBILT UNIVERSITY
    Inventors: James E. Crowe, Jr., Scott A. Smith, Terence Dermody, Laurie Silva
  • Patent number: 11345741
    Abstract: The present disclosure is directed to antibodies binding to and neutralizing the coronavirus designated SARS-CoV-2 and methods for use thereof.
    Type: Grant
    Filed: March 25, 2021
    Date of Patent: May 31, 2022
    Assignee: Vanderbilt University
    Inventors: James E. Crowe, Jr., Seth Zost, Robert Carnahan, Pavlo Gilchuk
  • Publication number: 20220080036
    Abstract: The present disclosure is directed to antibodies binding to and inhibiting S. aureus and methods for use thereof.
    Type: Application
    Filed: September 6, 2019
    Publication date: March 17, 2022
    Inventors: James E. Crowe, Jr., Eric Skaar
  • Publication number: 20210403538
    Abstract: The present disclosure is directed to human antibodies binding to and neutralizing ebolavirus and methods for use thereof. A further embodiment involves a monoclonal antibody, wherein the antibody or antibody fragment is characterized by clone-paired heavy and light chain CDR sequences. In yet another embodiment, there is provided a hybridoma or engineered cell encoding an antibody or antibody fragment. An additional embodiment comprises a vaccine formulation comprising one or more antibodies or antibody fragments characterized by clone-paired heavy and light chain CDR sequences. In still a further embodiment, there is provided a method of protecting the health of a placenta and/or fetus of a pregnant a subject infected with or at risk of infection with ebolavirus comprising delivering to said subject the antibody or antibody fragment.
    Type: Application
    Filed: July 11, 2019
    Publication date: December 30, 2021
    Inventors: James E. CROWE, Jr., Pavlo GILCHUK, Alexander BUKREYEV
  • Publication number: 20210347864
    Abstract: The present disclosure is directed to antibodies binding to and neutralizing Zika virus and methods for use thereof.
    Type: Application
    Filed: May 17, 2021
    Publication date: November 11, 2021
    Applicant: Vanderbilt University
    Inventor: James E. CROWE, Jr.
  • Publication number: 20210324051
    Abstract: The present disclosure is directed to antibodies binding to Marburg virus (MARV) glycoprotein (GP) and methods of use therefore.
    Type: Application
    Filed: July 1, 2021
    Publication date: October 21, 2021
    Inventors: James E. CROWE, Jr., Andrew I. FLYAK, Alexander BUKREYEV, Philipp ILINYKH